10th International Workshop on Waldenstrom’s Macroglobulinemia

Program Agenda

Co-Chairs:

Lia Palomba M.D., Memorial Sloan Kettering Cancer Center, New York NY, USA
Richard Furman M.D., Cornell Weill Cornell Medicine, New York, NY, USA
Jorge Castillo M.D., Dana Farber Cancer Institute, Boston MA, USA
Steven Treon M.D., PhD., Dana Farber Cancer Institute, Boston MA, USA

Thursday, October 11, 2018

6:30am  Registration and Coffee service

Session I  Genomics in the Diagnosis and Management of WM

Roger Owen, Chair

7:30am  How important is MYD88 mutation status for the diagnosis of WM?
Roger Owen, Leeds Teaching Hospitals NHS Trust

7:45am  What is the role of MYD88 and CXCR4 mutations in the management of WM?
Steven P. Treon, Dana Farber Cancer Institute, USA

8:00am  How should CXCR4 mutations be used in the treatment of WM patients?
Jorge J. Castillo, Dana Farber Cancer Institute, USA

8:15am  Can cell-free DNA be used to assess mutation status in WM?
Irene Ghobrial, Dana Farber Cancer Institute, USA

Session II  Predisposition to WM

Marzia Varettoni, Chair

8:30am  What IgM MGUS and smoldering WM patients are at risk for progression to active WM?
Robert A. Kyle, Mayo Clinic, USA

8:45am  Is detection of mutated MYD88 associated with progression of IGM MGUS?
9:00am  
*What genomic changes accompany transition of IgM MGUS to WM?*
Marzia Varettoni, University of Pavia, Italy

9:15am  
*What underlying genomics are responsible for familial WM?*
Bruno Paiva, University of Pamplona, Spain

9:30am  
*Genetic predisposition to WM is associated with B-cell activation outside germinal center*
Mary McMaster, National Institutes of Health, USA

9:45am  
*Is Agent Orange exposure associated with WM?*
Helga Ogmundsdottir, University of Iceland, Iceland

10:00am  
Morning Refreshments

**Session III**  
**Disease Presentation in WM**  
*Pierre Morel, Chair*

10:15am  
*How should patients with WM related peripheral neuropathy be evaluated?*
Shirley D’SAA, University College London Hospitals NHS Trust, London, UK

10:30am  
*What is the spectrum of presentation associated with anti-MAG antibodies?*
Juliette Svahn, University Hospital Lyon, France

10:45am  
*How should patients with Bing Neel Syndrome be evaluated?*
Monique Minnema, UMC Utrecht Cancer Center, The Netherlands

11:00am  
*When should plasmapheresis be used in the management of WM?*
Marvin Stone, University of Texas, USA

11:15am  
**Keynote Lecture**

*The pathophysiology of IgM related neuropathy*

**Keynote Speaker:** Eduardo Nobile-Orazio, University of Milan, Italy

11:30-12:45pm LUNCH
Session IV  Genomic Landscape of WM

Nikhil Munshi, Chair

12:30pm  What are the important genomic findings in WM?
Zachary Hunter, Dana Farber Cancer Institute, USA

12:45pm  Are losses in 6q important to WM growth and survival?
ML Guerrera, Dana Farber Cancer Institute, USA

1:00pm  Do TP53 mutations impact outcome in WM?
Stephanie Poulain, CHRU-Lille, France

1:15pm  What mutations accompany disease transformation in WM?
Cristina Jimenez, University of Salamanca, Spain

1:30pm  Keynote Lecture
Is there spatial genomic heterogeneity in plasma cell malignancies?
Keynote Speaker: Gareth Morgan, University of Arkansas, USA

1:45pm  Keynote Lecture
Is genomic evolution predictable in plasma cell malignancies?
Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA

2:00pm  Afternoon refreshments

Session V  Mechanisms of Tumor Growth and Survival in WM

Douglas Joshua, Chair

2:15pm  How do MYD88 mutations impact WM cell growth and survival?
Guang Yang, Dana Farber Cancer Institute, USA

2:30pm  Are MYD88 mutations by themselves sufficient to cause WM?
Ruben Carrasco, Harvard Medical School, USA

2:45pm  Do genomics impact cytokine related signaling in WM?
Josephine Vos, University of Amsterdam, The Netherlands

3:00pm  How does the microenvironment impact WM cell growth and drug resistance?
ST Pals, University of Amsterdam, The Netherlands
3:15pm  **Keynote Lecture**  
*Do exosomes play a role in propagating mutated MYD88 signaling?*

**Keynote Speaker:** Roman Jerala, National Chemistry Institute, Slovenia

---

**Session VI**  
**Oral Presentations I (Selected from Submitted Abstracts)**

*MJ Kersten and Zachary R. Hunter, Co-Chairs*

3:30pm  
**MYD88 L265P mutation in IgM MGUS: Detection by droplet digital PCR**

Simone Ferrero, University of Torino, Italy

3:45pm  
**Progression risk-based classification of Asymptomatic WM**

Mark Bustoros, Dana Farber Cancer Institute, USA

4:00pm  
**Clonality Assessment of CXCR4 S338X predicts outcomes to ibrutinib in WM**

Joshua Gustine, Dana Farber Cancer Institute, USA

4:15pm  
Characterization of endogenous CXCR4 inhibitory peptides to target WM

LM Kaiser, Comprehensive Cancer Center of Ulm, Germany

4:30pm  
**Day Adjournment**

---

5:30-6:00pm  
**Departures from Lobby for Ferry Boats to Ellis Island**

(All attendees must clear security at Battery Park Embarkation)

---

6:30pm  
**OPENING CEREMONY AT ELLIS ISLAND**

Young Investigator Poster Presentations and Awards

Presentation of Robert A. Kyle Award

Welcome Dinner Reception
**Friday, October 12, 2018**

7:00am  Registration and Coffee service

8:00am  **Late Breaking Abstract Lecture**

*Usefulness of time-dependent Cox model with cause-specific competing risk analyses for assessing prognosis during the course of Waldenström macroglobulinemia (WM).*

Bénédicte Hivert, CHRU de Lille, France

---

**Session VII**  Clinical Trials in WM: Rituximab-based therapy

*Eva Kimby, Chair*

8:15am  *Bendamustine and Rituximab in treatment naïve patients with WM*

Veronique Leblond, Hospital Pitie-Salpetriere, France

8:30am  *Long term efficacy of Rituximab in MAG positive peripheral neuropathy RIMAG study follow-up*

Jean Marc Leger, Hospital Pitié-Salpêtrière, France

8:45am  *Randomized clinical trial of BCR vs. FCR in treatment naïve WM patients*

Rebecca Auer, University College of London, UK

---

9:00am  **Keynote Lecture**

*Is there a standard of care for treating treatment naïve WM?*

**Keynote Speaker:** Adam Olszewski, Brown University, USA

---

9:15am  Morning Refreshments

---

**Session VIII**  Clinical Trial Updates in WM: Proteasome Inhibitors

*Christian Buske, Chair*

9:30am  *Long term follow-up of Bortezomib, Dexamethasone & Rituximab in treatment-naïve WM*

Stathis Kastritis, University of Athens, Greece
9:45am  Long term follow-up of Carfilzomib, Dexamethasone, Rituximab in treatment-naïve WM
Kirsten Meid, Dana Farber Cancer Institute, USA

10:00am  Prospective study of Carfilzomib in previously treated WM patients
David Vesole, Hackensack Medical Center, USA

10:15am  Ixazomib, Dexamethasone, Rituximab in previously-treated WM patients
M.J. Kersten, University of Amsterdam, The Netherlands

Session IX  Clinical Trials Updates in WM: Ibrutinib
Lia Palomba, Chair

10:30am  Ibrutinib monotherapy in treatment-naïve WM patients
Steven Treon, Dana Farber Cancer Institute, USA

10:45am  Long term follow-up of ibrutinib monotherapy in previously-treated WM patients:
Update of pivotal trial
Ranjana Advani, Stanford University Medical Center, USA

11:00am  Ibrutinib monotherapy in rituximab-refractory WM patients
Judith Trotman, University of Sydney, Australia

11:15am  Randomized study of ibrutinib/rituximab versus rituximab in symptomatic WM patients
Meletios Dimopoulos, University of Athens, Greece

11:30-12:30pm  LUNCH

Session X  Clinical Trials Updates in WM: Novel Agents and Trials in Progress
Meletios Dimopoulos, Chair

12:30pm  Phase II Study of the BTK-inhibitor Acalabrutinib in previously-treated WM patients
Rick Furman, Weill Cornell Medical College, USA

12:45pm  Phase II Study of the BTK-inhibitor Zanubrutinib in symptomatic WM patients
Constantine Tam, University of Melbourne, Australia
1:00pm  *Phase III Study of Zanubrutinib vs. Ibrutinib in symptomatic WM patients*
Jane Huang, Beigene, USA

1:15pm  *Phase II Study of the BCL2-inhibitor Venetoclax in previously treated WM patients*
Jorge J. Castillo, Dana Farber Cancer Institute, USA

1:30pm  *Phase I/II Study of CXCR4-inhibitor Ulocuplomab plus ibrutinib in symptomatic WM*
Steven P. Treon, Dana Farber Cancer Institute, USA

1:45pm  *Phase II Study of the CD38-antibody Daratumumab in previously treated WM patients*
Jorge Castillo, Dana Farber Cancer Institute, USA

**Session XI**  
Ibrutinib Resistance in WM  
*Richard Furman, Chair*

**Afternoon refreshments will be served during the Session at the back of the Hall**

2:00pm  *What mutations are associated with resistance to BTK-inhibitors in WM?*
Lian Xu, Dana Farber Cancer Institute, USA

2:15pm  *What are the mechanisms of resistance to ibrutinib in WM?*
Guang Yang, Dana Farber Cancer Institute, USA

2:30pm  *Does BCL2 play a role in ibrutinib resistance?*
Matt Davids, Dana Farber Cancer Institute, USA

2:45pm  **Keynote Lecture**  
*Evolutional Landscape of Ibrutinib Resistance*  
**Keynote Speaker:** Dan Landau, Weill Cornell Medical College, USA

3:00pm  **Keynote Lecture**  
*Understanding and overcoming ibrutinib resistance in B-cell malignancies*  
**Keynote Speaker:** Adrian Wiestner, National Institutes of Health, USA
Session XII  Oral Presentations II (Selected from Submitted Abstracts)

Judy Trotman and Ranjana Advani, Co-Chairs

3:15pm  Development of novel IRAK1 inhibitors for treatment of WM  
Xia Liu, Dana Farber Cancer Institute

3:30pm  CANOMAD: Clinical, Biological, Electrophysiological and Treatment Analysis  
Marie Le Cann, CHU Hopital Pitie-Salpetriere, France

3:45pm  Ibrutinib Therapy in WM: Outcomes Outside a Clinical Trial  
J. Abeykoon, Mayo Clinic, USA

4:00pm  Phase II Study of Idelalisib and Obinutuzumab in relapsed/refractory WM  
C. Tomowiak, CHU de Poitiers, France

4:15pm  Phase II Study of Bendamustine, Rituximab, Bortezomib in relapsed/refractory WM  
G. Benevolo, Fondazione Italiana Linfomi ONLUS, Italy

4:30pm  POSTER PRESENTATIONS AND RECEPTION

5:00-6:00pm POSTER DISCUSSIONS

Ranjana Advani and Marvin Stone, Co-Chairs

Incidence and inheritance of hyperphosphorylated paratag-7 in WM  
L. Brandefors, Karolinska Institut, Sweden

Assessment of molecular response by RT-PCR for MYD88 L265P  
I. Defrancesco, Fondazione IRCCS Policlinico San Matteo, Italy

Real Life Outcome of LP5 and SMZL: Analysis of NF10 Project  
L. Arcaini, University of Pavia, Italy

CD38 as a novel therapeutic target in WM  
Paulus, Mayo Clinic Jacksonville, FL

Significance of residual neoplastic cells by flow cytometry in R2W Trial  
Ruth de Tute, St. James Institute of Oncology, UK

7:00pm  FACULTY RECEPTION AND DINNER AT PIER A HARBOR HOUSE

(By Invitation; Faculty Departs Lobby at 6:45pm)
Saturday, October 13, 2018

7:30am Registration and Coffee service

8:00am **Keynote Lecture**

*What are the new targets for drug development in WM?*

**Keynote Speaker:** Sara Buhrlage, Harvard Medical School, USA

**Session XIII** Specialized Treatment Approaches to WM  
*JP Fermand, Chair*

8:15am *How should the WM patient with amyloidosis be cared for?*  
Giampaolo Merlini, University of Pavia, Italy

8:30am *How should Bing Neel Syndrome be treated?*  
Monique Minnema, UMC Utrecht Cancer Center, The Netherlands

8:45am *When is autologous transplant appropriate for WM patients?*  
Charalampia Kyriakou, University College Hospital of London, UK

9:00am *In which WM patients is CAR-T-cell therapy appropriate?*  
Lia Palomba, Memorial Sloan Cancer Center, USA

9:15am Morning Refreshments

**Session XIV** Panel Discussions on Treatment Approaches to WM  
*Veronique Leblond and Meletios Dimopoulos, Chairs*

9:30am *Should MYD88 and CXCR4 mutation status impact treatment decision making?*  
Roger Owen, MJ Kersten, Constantine Tam, Marzia Varettoni, Jorge Castillo

10:00am *What is the goal of therapy in WM: Complete Response or Disease Control?*  
Stathis Kastritis, Lia Palomba, Alessandra Tedeschi, Roger Owen, Christian Buske

10:30am *How do you manage ibrutinib related side effects and withdrawal syndrome?*  
Jorge Castillo, Richard Furman, Ranjana Advani, Judith Trotman, Christian Buske,  
Adrian Wiestner
11:00am  **Should rituximab maintenance be offered to all patients?**
Ranjana Advani, Stathis Kastritis, Richard Furman, Judith Trotman, Eva Kimby

11:30am  **What is the optimal treatment approach to IgM related peripheral neuropathy?**
Jorge Castillo, Eduardo Nobile-Orazio, Veronique LeBlond, Shirley D’Sa, JM Leger, Juliette Svahn

12:00-1:00pm  LUNCH

**Session XV**  Associated and Secondary Malignancy Risks in WM Patients
*Alessandra Tedeschi, Chair*

1:00pm  **Are WM patients at higher risk for treatment unrelated cancers?**
Jorge Castillo, Dana Farber Cancer Institute, USA

1:15pm  **Should additional cancer screening measures be adopted for WM patients?**
Stathis Kastritis, University of Athens, Greece

1:30pm  **Therapy-related myeloid neoplasms: Insights from UK R2W Trial**
R. Owen, St. James Institute of Oncology, UK

1:45pm  **How important are treatment related secondary malignancies in WM?**
Alessandra Tedeschi, Niguarda Hospital, Italy

**Afternoon refreshments will be served during the Session at the back of the Hall**

**Session XVI**  Consensus Panel Discussions
*Steven P. Treon and Meletios Dimopoulos, Co-Chairs*

2:00pm  **Diagnostic Markers in WM**
Discussants: J. Castillo/ S. Kastritis

2:30pm  **Treatment Recommendations for WM and IgM Related Disorders**
Discussants: S. Treon/M. Dimopoulos
3:00pm  
*Priority Clinical Trials for WM*
Discussants: V. LeBlond/MJ Kersten

3:30pm  
Day Adjournment

5:00pm  
**Bus Departures from Lobby to United Nations Plaza**

6:00pm  
**CLOSING CEREMONY AT UNITED NATIONS**
(All attendees must clear security at UN Pavilion)

Tour of General Assembly and Security Council

Farewell Dinner Reception at United Nations Delegates Banquet Hall

Awards Ceremony

Presentation of Jan Gosta Waldenstrom Award

Presentation of WM Innovation Award

Presentation of WM Humanitarian Awards

Welcome to IWWM11